These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 28754782)

  • 1. CAR T Cells Infiltrate Brain, Target Tumors.
    Cancer Discov; 2017 Sep; 7(9):926. PubMed ID: 28754782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma.
    O'Rourke DM; Nasrallah MP; Desai A; Melenhorst JJ; Mansfield K; Morrissette JJD; Martinez-Lage M; Brem S; Maloney E; Shen A; Isaacs R; Mohan S; Plesa G; Lacey SF; Navenot JM; Zheng Z; Levine BL; Okada H; June CH; Brogdon JL; Maus MV
    Sci Transl Med; 2017 Jul; 9(399):. PubMed ID: 28724573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting EGFRvIII for glioblastoma multiforme.
    Yang J; Yan J; Liu B
    Cancer Lett; 2017 Sep; 403():224-230. PubMed ID: 28649003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-EGFRvIII Chimeric Antigen Receptor-Modified T Cells for Adoptive Cell Therapy of Glioblastoma.
    Ren PP; Li M; Li TF; Han SY
    Curr Pharm Des; 2017; 23(14):2113-2116. PubMed ID: 28302023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel Human NK Cell Line Carrying CAR Targeting EGFRvIII Induces Antitumor Effects in Glioblastoma Cells.
    Murakami T; Nakazawa T; Natsume A; Nishimura F; Nakamura M; Matsuda R; Omoto K; Tanaka Y; Shida Y; Park YS; Motoyama Y; Nakagawa I; Yamada S; Tamura K; Takeshima Y; Takamura Y; Wakabayashi T; Nakase H
    Anticancer Res; 2018 Sep; 38(9):5049-5056. PubMed ID: 30194149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticancer drugs: On-site CAR parking.
    Bray N
    Nat Rev Drug Discov; 2015 Apr; 14(4):235. PubMed ID: 25829274
    [No Abstract]   [Full Text] [Related]  

  • 7. Novel mechanisms and approaches in immunotherapy for brain tumors.
    Finocchiaro G; Pellegatta S
    Discov Med; 2015; 20(108):7-15. PubMed ID: 26321082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma.
    Brown CE; Badie B; Barish ME; Weng L; Ostberg JR; Chang WC; Naranjo A; Starr R; Wagner J; Wright C; Zhai Y; Bading JR; Ressler JA; Portnow J; D'Apuzzo M; Forman SJ; Jensen MC
    Clin Cancer Res; 2015 Sep; 21(18):4062-72. PubMed ID: 26059190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The EGFR variant III mutant as a target for immunotherapy of glioblastoma multiforme.
    Chistiakov DA; Chekhonin IV; Chekhonin VP
    Eur J Pharmacol; 2017 Sep; 810():70-82. PubMed ID: 28583430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lenalidomide enhances the function of chimeric antigen receptor T cells against the epidermal growth factor receptor variant III by enhancing immune synapses.
    Kuramitsu S; Ohno M; Ohka F; Shiina S; Yamamichi A; Kato A; Tanahashi K; Motomura K; Kondo G; Kurimoto M; Senga T; Wakabayashi T; Natsume A
    Cancer Gene Ther; 2015 Oct; 22(10):487-95. PubMed ID: 26450624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T-cell therapy targets glioblastoma.
    Cancer Discov; 2015 May; 5(5):458. PubMed ID: 25783861
    [No Abstract]   [Full Text] [Related]  

  • 12. Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma.
    Choi BD; Gerstner ER; Frigault MJ; Leick MB; Mount CW; Balaj L; Nikiforow S; Carter BS; Curry WT; Gallagher K; Maus MV
    N Engl J Med; 2024 Apr; 390(14):1290-1298. PubMed ID: 38477966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How fine a slice: treatment of newly diagnosed glioblastoma with an epidermal growth factor receptor variant III peptide vaccine.
    Chamberlain MC
    J Clin Oncol; 2011 Jun; 29(17):e517-8; author reply e519-20. PubMed ID: 21555685
    [No Abstract]   [Full Text] [Related]  

  • 14. Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer.
    Feng K; Guo Y; Dai H; Wang Y; Li X; Jia H; Han W
    Sci China Life Sci; 2016 May; 59(5):468-79. PubMed ID: 26968708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-CD3 x EGFR bispecific antibody redirects cytokine-induced killer cells to glioblastoma in vitro and in vivo.
    Ma P; He Q; Li W; Li X; Han H; Jin M; Liu C; Tao H; Ma J; Gao B
    Oncol Rep; 2015 Nov; 34(5):2567-75. PubMed ID: 26323605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases.
    Chen X; Han J; Chu J; Zhang L; Zhang J; Chen C; Chen L; Wang Y; Wang H; Yi L; Elder JB; Wang QE; He X; Kaur B; Chiocca EA; Yu J
    Oncotarget; 2016 May; 7(19):27764-77. PubMed ID: 27050072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells.
    Wang MY; Lu KV; Zhu S; Dia EQ; Vivanco I; Shackleford GM; Cavenee WK; Mellinghoff IK; Cloughesy TF; Sawyers CL; Mischel PS
    Cancer Res; 2006 Aug; 66(16):7864-9. PubMed ID: 16912159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma.
    Zhang C; Burger MC; Jennewein L; Genßler S; Schönfeld K; Zeiner P; Hattingen E; Harter PN; Mittelbronn M; Tonn T; Steinbach JP; Wels WS
    J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26640245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor.
    Jungbluth AA; Stockert E; Huang HJ; Collins VP; Coplan K; Iversen K; Kolb D; Johns TJ; Scott AM; Gullick WJ; Ritter G; Cohen L; Scanlan MJ; Cavenee WK; Old LJ
    Proc Natl Acad Sci U S A; 2003 Jan; 100(2):639-44. PubMed ID: 12515857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T-cells fighting B-cell lymphoproliferative malignancies: the emerging field of CD19 CAR T-cell therapy.
    Heijink DM; Kater AP; Hazenberg MD; Hagenbeek A; Kersten MJ
    Neth J Med; 2016 May; 74(4):147-51. PubMed ID: 27185772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.